Medicure Inc - Asset Resilience Ratio
Medicure Inc (MPH) has an Asset Resilience Ratio of 0.00% as of December 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2019)
This chart shows how Medicure Inc's Asset Resilience Ratio has changed over time. Check Medicure Inc (MPH) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Medicure Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Medicure Inc (MPH) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 0% |
| Short-term Investments | CA$0.00 | 0% |
| Total Liquid Assets | CA$0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Medicure Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Medicure Inc Industry Peers by Asset Resilience Ratio
Compare Medicure Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 28.06% |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623 |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Zhejiang Medicine Co Ltd
SHG:600216 |
Drug Manufacturers - Specialty & Generic | 1.85% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Annual Asset Resilience Ratio for Medicure Inc (2018–2019)
The table below shows the annual Asset Resilience Ratio data for Medicure Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | 0.00% | CA$0.00 ≈ $0.00 |
CA$42.28 Million ≈ $30.59 Million |
-- |
| 2018-12-31 | 46.02% | CA$47.75 Million ≈ $34.54 Million |
CA$103.76 Million ≈ $75.06 Million |
-- |
About Medicure Inc
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary … Read more